Read the results alongside the study design, safety findings and limitations.

Who was studied?

54 patients with metastatic solid tumors refractory to standard systemic therapy; response rates use the 54-patient ITT denominator, and safety analyses include 50 patients.

54Enrolled
16.7%ORR · ITT
4.0 monthsMedian PFS
10.5 monthsMedian OS

What does the publication report?

In the intention-to-treat population, ORR was 16.7% and DCR 46.3%. Median PFS was 4.0 months and median OS 10.5 months.

Reading the original figures

Treatment timeline showing radiotherapy, PD-1 inhibition, GM-CSF, maintenance therapy and imaging assessments.View full size ↗
How the original study combined treatment

Read from left to right: repeated radiotherapy and immune-treatment cycles were followed by maintenance treatment and imaging assessments. This is the schedule of the 2022 study, rather than a universal schedule for every PRaG-derived approach.

© 2022 Kong et al. · Frontiers in Immunology, 2022 · Figure 1 · CC BY 4.0. Reproduced without alteration.

Waterfall plot with both growth and shrinkage of nonirradiated target lesions, labeled with response categories.View full size ↗
Responses beyond the irradiated sites

Each bar represents one response-evaluable patient. Bars below zero show shrinkage of nonirradiated target lesions; bars above zero show growth. Both responses and progression are visible. CR, PR, SD and PD denote the authors’ response categories; this uncontrolled study cannot establish superiority over another treatment.

© 2022 Kong et al. · Frontiers in Immunology, 2022 · Figure 3 · CC BY 4.0. Reproduced without alteration.

Kaplan–Meier curves for progression-free and overall survival in the original phase II cohort.View full size ↗
Following outcomes over time

The left curve shows progression-free survival and the right overall survival in the study population. Time runs horizontally in months; the vertical axis shows the estimated proportion remaining without an event. These curves describe the cohort and are not predictions for an individual patient.

© 2022 Kong et al. · Frontiers in Immunology, 2022 · Figure 4 · CC BY 4.0. Reproduced without alteration.

Safety findings

Among 50 safety-assessed patients, five (10.0%) had grade 3 and one (2.0%) grade 4 treatment-related adverse events.

How should we interpret it?

Single-arm design, heterogeneous cancers and a small sample prevent a causal comparison with standard care.

Read the original source

This independently written summary was checked against the original full publication. It is an educational summary, not a full-paper translation or clinical recommendation.

PD-1 Inhibitor Combined With Radiotherapy and GM-CSF (PRaG) in Patients With Metastatic Solid Tumors: An Open-Label Phase II Study · DOI: 10.3389/fimmu.2022.952066 · PMID: 35874780

Educational reporting, not individualized medical advice. Discuss treatment decisions with your clinical team.